Investor Alert: Holzer Holzer & Fistel, LLC Advises Investors of Upcoming Deadlines in Shareholder Litigation Involving

Investor Alert: Holzer Holzer & Fistel, LLC Advises Investors of Upcoming 
Deadlines in Shareholder Litigation Involving magicJack
VocalTec LTD., Tellabs, Inc. and Keryx Biopharmaceuticals 
ATLANTA, GA -- (Marketwire) -- 02/13/13 --  Holzer Holzer & Fistel
LLC reminds investors of upcoming deadlines for applications to serve
as lead plaintiff in securities class action lawsuits against
magicJack VocalTec LTD (CALL), Tellabs, Inc. (TLAB) and Keryx
Biopharmaceuticals, Inc. (KERX). 
Investors that suffered significant losses investing in any of these
companies during the specified times who are interested in
potentially serving as lead plaintiff in the respective class actions
are encouraged to contact Michael I. Fistel, Jr., Esq.
(mfistel@holzerlaw.com) or Marshall P. Dees, Esq.
(mdees@holzerlaw.com) by email or via toll-free telephone at (888)
508-6832 to discuss their legal rights. 
magicJack VocalTec LTD  
A class action lawsuit has been filed on behalf of investors who
purchased magicJack (NASDAQ: CALL) securities between February 28,
2012 and January 8, 2013. The lawsuit alleges the company violated
the federal securities laws by, among other things, allegedly
overstating the Company's earnings, revenue and cash flows during
that time. 
The deadline to seek appointment as lead plaintiff in this lawsuit,
which is pending in the United States District Court for the Southern
District of New York, is March 19, 2013. More information about the
lawsuit and the firm are available at www.holzerlaw.com. 
Tellabs, Inc. 
A class action lawsuit has been filed on behalf of investors who
purchased Tellabs Inc. (NASDAQ: TLAB) common stock between October
26, 2010 and April 26, 2011, inclusive, alleging the company violated
the federal securities laws by making false and misleading statements
relating to, among other things, demand for its products and earnings
guidance during that time. 
The deadline to seek appointment as lead plaintiff in this lawsuit,
which is pending in the United States District Court for the Northern
District of Illinois, is March 25, 2013. More information about the
lawsuit and the firm are available at www.holzerlaw.com. 
Keryx Biopharmaceuticals, Inc. 
A class action lawsuit has been filed on behalf of investors who
purchased Keryx (NASDAQ: KERX) common stock between June 1, 2009 and
April 1, 2012. According to the complaint, the company is alleged to
have violated the federal securities laws by issuing false and
misleading statements regarding its phase 3 clinical trial of
perifosine. 
The deadline to seek appointment as lead plaintiff in this lawsuit,
which is pending in the United States District Court for the Southern
District of New York, is April 2, 2013. More information about the
lawsuit and the firm are available at www.holzerlaw.com. 
About The Firm 
Holzer Holzer & Fistel, LLC dedicates its practice to vigorous
representation of shareholders and investors in litigation
nationwide, including shareholder class action and derivative
litigation. More information about the firm is available through its
website, www.holzerlaw.com and upon request from the firm. Holzer
Holzer & Fistel, LLC has paid for the dissemination of this
promotional communication, and Michael I. Fistel, Jr. is the attorney
responsible for its content. 
CONTACT: 
Michael I. Fistel, Jr., Esq.
Marshall P. Dees, Esq.
Holzer Holzer & Fistel, LLC
200 Ashford Center North, Suite 300
Atlanta GA 30338
(888) 508-6832 (toll-free)
mfistel@holzerlaw.com
mdees@holzerlaw.com 
 
 
Press spacebar to pause and continue. Press esc to stop.